載入中
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
前收盤價
US$2.91
+US$0.12 · +4.30%
盤中時間採用ET。市場資料可能有所延遲。
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
日內區間
目前US$2.91
52週區間
目前US$2.91
盤中時間採用ET。市場資料可能有所延遲。
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
日內區間
目前US$2.91
52週區間
目前US$2.91
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3511.3萬 USD | 255.7萬 USD | — | — | — |
| 銷貨成本 | 625.7萬 USD | 79.7萬 USD | — | — | 189.2萬 USD |
| 毛利 | 2885.6萬 USD | 176萬 USD | — | — | −189.2萬 USD |
| 研究與開發 | 7222.3萬 USD | 8164.3萬 USD | 7201.7萬 USD | 6105.8萬 USD | 4875.5萬 USD |
| 銷售、一般及管理費用 | 4351.6萬 USD | 6151.8萬 USD | 3550.5萬 USD | 2702萬 USD | 2470.2萬 USD |
| 營業費用 | 1.16億 USD | 3816.1萬 USD | 1.08億 USD | 8756.9萬 USD | 7345.7萬 USD |
| 利息收入 | 457.6萬 USD | 576.9萬 USD | 458.2萬 USD | 21.9萬 USD | 1萬 USD |
| 利息支出 | 887.6萬 USD | 876.8萬 USD | 577.7萬 USD | 399.3萬 USD | 364.2萬 USD |
| 折舊和攤銷 | 127.7萬 USD | 79.6萬 USD | 41.9萬 USD | 51.3萬 USD | 189.2萬 USD |
| 營業利益 | −8688.3萬 USD | −3640.1萬 USD | −1.08億 USD | −8756.9萬 USD | −7534.9萬 USD |
| 淨利 | −7919.9萬 USD | −3745萬 USD | −1.01億 USD | −9386.7萬 USD | −8869.6萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1050.15萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM606.22萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF414.08萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO187.66萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC74.05萬0.06%13.17億 USD0.60%US$183+0.11%
ALPS Medical Breakthroughs ETFSBIO36.37萬0.19%1.91億 USD0.50%US$55.04+2.03%
Vanguard Russell 2000 Value ETFVTWV30.26萬0.02%14億 USD0.06%US$185.81-0.13%
Avantis U.S. Small Cap Equity ETFAVSC29.73萬0.01%30.82億 USD0.25%US$69.98+0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOVanguard Russell 2000 Value ETFVTWVAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
